We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are OK with this.     OK  No, I would like to know more...
Home / Products & Services / Biopharmaceuticals / Contract manufacturing services / CMO Services for Viruses & Viral Vectors
CMO Services for Viruses & Viral Vectors
Biopharmaceuticals

CMO Services for Viruses & Viral Vectors

Bdbioph2

A complete outsourcing solution

For more than 15 years, Novasep has aquired experience in manufacturing attenuated or wild type viruses and viral vectors. Our track record includes:Novasep VERO Cells On Microcarrier CMO Virus

  • Gene and cancer therapies,
  • Vectorized vaccines,
  • Live or killed viral vaccines,
  • Virus-like particles
  • Rec-proteins expression (e.g. via baculovirus/insect cells)

Novasep offers a full range of services adapted to your needs, from L1 up to L3 containment levels, including:

  • 6 R&D labs and 10 cGMP suites designed for the containment of BSL2/BSL3 pathogens
  • A clear methodology for technical and analytical methods transfer
  • Full USP and DSP capabilities from process development up to clinical trial material manufacturing
  • A broad expertise in single-use and reusable technologies for culture and purification
  • Full analytical development and qualification (including virus-specific potency, identity and transgene expression assays such as TCID50, IFA and qPCR)

 

An efficient methodology for virus and viral vector manufacturing

We can address all manufacturing needs thanks to a strong mastery of both cultivation and purification technologies as well as virus-dedicated process development methodology:

  • Full process and analytical transfer
  • Upstream process development
    • Cell line adaptation to serum-free, suspension growth
    • Development Cell & Virus Banks
    • Cell culture development (parameters, feeding strategy…)
    • Single-use and stainless steel bioreactors: from 3 to 1,000 L
    • Viral infection and viral DNA transfection procedure development
    • Lysis conditions development
  • Downstream process development
    • Clarification development
    • Development of purification steps (filtration and chromatography)
    • Development of virus inactivation
  • Process scale-up
  • cGMP material production
    • Cell Banks (MCB, WCB), Virus Seeds (MVS, WVS) and Drug Substance
  • Process validation

 

Specific know-how in AAV, ADV and lentiviruses …

Novasep has a strong track record and focus on AAV, ADV and Lentiviruses because of their attractive features for gene therapy or vaccination:

  • Lentiviruses (e.g HIV, EIAV) can stably transfer therapeutic genes into both dividing and non-dividing cells. They represent a tool of choice for long-term expression, especially for the treatment of genetic diseases.
  • Adenoviruses advantages are numerous: high transduction efficiency, high level of transgene expression, large tropism. ADV can transiently infect both dividing and non-dividing cells.
  • Adeno-Associated Viruses are non-pathogenic. AAV are able to mediate long-term gene expression for correcting genetic or acquired diseases. The numerous pseudotypes currently available allow them to transduce a large variety of target tissue types.

 

…and many other viruses and viral vectors

Each virus family exhibits specific properties such as: structural diversity, infectivity, pathogenicity and degree of resistance to physical-chemical treatments. Consequently, viral vector production can be very challenging. Therefore, our solid CMO track record will be instrumental in bringing your project to success:

Type Family Production System Application Maximum
Scale
Lentiviral vectors

Retroviridae

EIAV/HIV-1

HEK-293T cells

Static

Gene Therapy

Clinical trials

25 CF10

15HS36

Venezuelian Equine Encephalitis-derived replicon particles Togoviridae

VERO cells

Static

Vaccination

Clinical trials

24 T150

Highly attenuated recombinant VSV Rhabdoviridae

VERO cells

Microcarrier/BR

Vaccination

Clinical trials

10L SUB

Recombinant Measles Virus Paramyxoviridae

MRC5

Static

Aseptic process

Vaccination

Clinical trials

24 CF10

Attenuated Influenza Virus (A&B) Orthomyxoviridae

VERO cells

Static

Vaccination

Clinical trials

15 CF10

Recombinant attenuated Dengue Virus Flaviviridae

VERO cells

Microcarrier/BR

Vaccination

Pre-clinical

50L SUB

H-1 virus Parvoviridae

Human T-cells

Wave BR

Cancer Therapy

R&D

25L SUB

Baculovirus vectors encoding for VLP Baculoviridae

Sf9 or Hi-5

BR

Vaccination


Immunotherapy

Clinical trials

50L SUB

Baculovirus vectors encoding for recombinant proteins
Downloads
  • Global offer for biopharmaceuticals
    Global offer for biopharmaceuticals
    size: 140.8K
    date: 08/12/2014
  • Viral vector and virus manufacturing services
    Viral vector and virus manufacturing services
    size: 2.3M
    date: 08/12/2014
  • ADC Brochure
    ADC Brochure
    size: 672.1K
    date: 20/10/2015
Contact
You can stay on this page and select more documents or you can directly download the brochure(s) you selected